Edition:
United States

argenx NV (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

59.47USD
14 Dec 2017
Change (% chg)

$6.74 (+12.78%)
Prev Close
$52.73
Open
$58.16
Day's High
$69.00
Day's Low
$58.16
Volume
799,767
Avg. Vol
28,374
52-wk High
$69.00
52-wk Low
$17.42

Latest Key Developments (Source: Significant Developments)

Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering
Wednesday, 13 Dec 2017 07:27pm EST 

Dec 14 (Reuters) - Argenx Nv ::ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING.‍ARGENX HAS GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 666,000 ADSS​.‍PRICING OF ITS PUBLIC OFFERING IN UNITED STATES WITH ANTICIPATED GROSS PROCEEDS ABOUT $231 MILLION FROM SALE OF 4,440,000 ADSS, AT $52/ADS​.  Full Article

Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS
Wednesday, 13 Dec 2017 06:00am EST 

Dec 13 (Reuters) - Argenx Nv ::HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS.NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF ADSS IN PROPOSED OFFERING ARE TO BE SOLD BY ARGENX..  Full Article

Argenx Files For Offering Of Up To $150 Mln American Depositary Shares
Monday, 11 Dec 2017 04:19pm EST 

Dec 11 (Reuters) - Argenx Nv ::ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Argenx announces launch of proposed public offering in United States
Monday, 11 Dec 2017 04:10pm EST 

Dec 11 (Reuters) - Argenx Nv ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.ARGENX NV - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF AMERICAN DEPOSITARY SHARES.ARGENX NV - EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110
Monday, 11 Dec 2017 01:05am EST 

Dec 11 (Reuters) - ARGENX NV ::TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.  Full Article

Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113
Monday, 11 Dec 2017 01:00am EST 

Dec 11 (Reuters) - Argenx Nv ::REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113.FAVORABLE TOLERABILITY PROFILE CONSISTENT WITH PHASE 1 DATA.ARGX-113 TREATMENT RESULTED IN A STRONG CLINICAL IMPROVEMENT OVER PLACEBO DURING ENTIRE DURATION OF STUDY.75% OF ARGX-113 TREATED PATIENTS HAD SIGNIFICANT IMPROVEMENT IN 6 WEEKS VERSUS 25% OF PATIENTS ON PLACEBO.TOPLINE DATA FOR ITP TRIAL EXPECTED IN H2 2018.INTERIM DATA FROM PV TRIAL EXPECTED IN H2 2018.ARGX-113 (EFGARTIGIMOD) IS USED IN GENERALIZED MYASTHENIA GRAVIS.  Full Article

Argenx launches phase I trial with subcutaneous formulation of ARGX-113​
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - ARGENX NV ::‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​.‍PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS​.‍TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018.‍INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018.​.  Full Article

Argenx 9M total comprehensive loss widens to 16.5 million euros
Thursday, 26 Oct 2017 01:00am EDT 

Oct 26 (Reuters) - ARGENX NV ::REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.9M TOTAL OPERATING INCOME EUR ‍​30.5 MILLION VERSUS EUR 12.5 MILLION YEAR AGO.9M TOTAL COMPREHENSIVE LOSS OF €16.5 MILLION (SEPTEMBER 30, 2016: LOSS €12.6 MILLION).‍​.AS OF SEPT 30 CASH POSITION OF €161.7 MILLION‍​.  Full Article

ArgenX cash and cash equivalents at end H1 stood at 173.4 million euros
Thursday, 24 Aug 2017 01:00am EDT 

Aug 24 (Reuters) - ARGENX NV ::H1 LOSS BEFORE TAXES EUR 7.6 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO.H1 OPERATING LOSS EUR 6.8 MILLION VERSUS LOSS OF EUR 7.4 MILLION YEAR AGO.H1 REVENUE EUR 22.4 MILLION VERSUS EUR 5.7 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT END H1 EUR 173.4 MILLION VERSUS EUR 108.7 MILLION YEAR AGO.  Full Article

Argenx receives 2nd preclinical milestone payment in Leo Pharma collaboration
Tuesday, 20 Jun 2017 01:00am EDT 

June 20 (Reuters) - ARGENX NV :REG-ARGENX RECEIVES SECOND PRECLINICAL MILESTONE PAYMENT IN COLLABORATION WITH LEO PHARMA.  Full Article

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS